Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: FlatTaxMan who wrote (7)	11/7/1998 4:45:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1833

>> Anybody know why the stock recently has been going up? << exchange2000.com Big accumulation across the sector.

To: FlatTaxMan who wrote (7)	11/8/1998 1:18:00 AM
From: Dave K	Respond to of 1833

Can't find anything specific. Third Q results were released on the 4th. Did not see anything special except that Chuck was appointed to the board and lots of R&D spending. A large purchase and jump early on the 5th may have coincided with overall uptick in small biotech sector and Geron mania. Geze, If I hear or read another stem cell story I'll expletive... Cadus was selling well under book for the last few or so. Now seems like it was a great opportunity :-).

To: FlatTaxMan who wrote (7)	12/3/1998 11:35:00 PM
From: Dave K	Read Replies (1) \| Respond to of 1833

Cadus Pharmaceutical Identifies Ligands for Human Orphan Receptor - Validation of Cadus' SSCL(TM) Reported in Nature Biotechnology - biz.yahoo.com "Christine Klein, Ph.D., primary author of the paper, used a proprietary Cadus technology, the Self-Selecting Combinatorial Library (SSCL™), to screen for the peptide surrogate ligands for FPRL-1. The surrogate ligands which were identified by the SSCL were tested against human cells that express the FPRL-1 receptor and the results suggest that the FPRL-1 receptor plays a role in the body's inflammatory response."